Clinical Study of Anlotinib in Maintenance Treatment of Advanced NSCLC
Phase of Trial: Phase II
Latest Information Update: 23 Oct 2019
Price : $35 *
At a glance
- Drugs Anlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms CSOAIMTOAN
- 20 Oct 2019 Planned primary completion date changed from 31 Dec 2019 to 31 Dec 2020.
- 20 Oct 2019 Status changed from not yet recruiting to recruiting.
- 14 Dec 2018 New trial record